Highbridge Capital Management LLC increased its position in shares of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) by 66.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 480,108 shares of the company’s stock after acquiring an additional 191,490 shares during the period. Highbridge Capital Management LLC owned about 2.04% of Aquinox Pharmaceuticals worth $1,407,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Prosight Management LP acquired a new position in Aquinox Pharmaceuticals during the 2nd quarter worth about $1,062,000. Acadian Asset Management LLC acquired a new position in Aquinox Pharmaceuticals during the 3rd quarter worth about $1,126,000. JPMorgan Chase & Co. acquired a new position in Aquinox Pharmaceuticals during the 3rd quarter worth about $823,000. Dimensional Fund Advisors LP increased its holdings in Aquinox Pharmaceuticals by 278.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 275,284 shares of the company’s stock worth $807,000 after purchasing an additional 202,514 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in Aquinox Pharmaceuticals during the 3rd quarter worth about $546,000. 77.60% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ AQXP opened at $2.30 on Friday. Aquinox Pharmaceuticals Inc has a 1-year low of $1.96 and a 1-year high of $16.90.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its quarterly earnings results on Thursday, November 8th. The company reported ($0.64) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.43).
Separately, ValuEngine upgraded Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, August 20th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $20.80.
TRADEMARK VIOLATION WARNING: “Highbridge Capital Management LLC Boosts Position in Aquinox Pharmaceuticals Inc (AQXP)” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/12/08/highbridge-capital-management-llc-boosts-position-in-aquinox-pharmaceuticals-inc-aqxp.html.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers.
Recommended Story: Why do corrections happen?
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.